This inventor holds 6 USPTO granted patents. Top assignees: Ciba-Geigy Corporation, Cancer Research Campaign Technology Limited, Novartis Ag. Active years: 1992-2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 6,858 
2 out of 62 
1 out of 3,978 
Years Active: 1992-2006
Title: Heinz-Kurt Hochkeppel: Innovator in Cancer Research
Introduction
Heinz-Kurt Hochkeppel is a notable inventor based in Aesch, Switzerland. He has made significant contributions to the field of cancer research, particularly through his innovative work on inhibitors that target the interaction between the p53 protein and MDM2. With a total of 6 patents to his name, Hochkeppel's inventions are paving the way for new therapeutic approaches in oncology.
Latest Patents
Hochkeppel's latest patents include groundbreaking inventions aimed at combating cancer. One of his notable patents focuses on inhibitors of the interaction between p53 and MDM2. This invention relates to compounds that can bind to the oncogene protein MDM2, along with processes for preparing these compounds and their pharmaceutical applications. These compounds are particularly useful in the therapeutic treatment of humans, as they inhibit the growth of tumor cells that contain the wild type p53 suppressor by disrupting the interaction between p53 and MDM2.
Another significant patent involves an assay for identifying inhibitors of the interaction between proteins p53 and dm2. This innovative assay allows for the identification of compounds that inhibit the formation of complexes between the dm2 gene product and p53, while preserving p53's ability to bind to DNA. The assay employs a gel shift procedure to detect complex formation and disruption, enabling the selection of compounds that maintain p53's conformation necessary for its function.
Career Highlights
Throughout his career, Hochkeppel has worked with prominent organizations, including Ciba-Geigy Corporation and Cancer Research Campaign Technology Limited. His work in these institutions has contributed to advancements in cancer research and therapeutic development.
Collaborations
Hochkeppel has collaborated with esteemed colleagues such as Jean Content and Michel A Horisberger. These partnerships have further enriched his research and innovation in the field.
Conclusion
Heinz-Kurt Hochkeppel's contributions to cancer research through his patents and collaborations highlight his role as a significant innovator in the field. His work continues to inspire advancements in therapeutic strategies for cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile